阿托伐汀联合福辛普利对心肌梗死PCI术后心血管不良事件的影响

Effects of atorvastatin combined with fosinopril on cardiovascular adverse events after PCI in myocardial infarction

目的探讨阿托伐他汀联合福辛普利对心肌梗死PCI术后心血管事件的影响。方法回顾性分析2018年9月至2019年10月于本院行经皮冠状动脉介入术(PCI)治疗的106例ST段抬高型心肌梗死(STEMI)患者的临床资料及随访结果,其中仅应用阿托伐他汀治疗患者作为A组(n=48),阿托伐他汀联合福辛普利治疗的患者作为B组(n=58),比较两组患者临床资料和术后2个月内的心血管不良事件发生情况。结果术后7 d,两组患者LVEF、LVEDD、CK-MB、cTnl水平比较差异无统计学意义。术后2个月,A组发生心血管不良事件9例,B组发生心血管不良事件3例,B组心血管不良事件发生率低于A组(χ(2)=4.823,P=0.028)。结论阿托伐汀联合福辛普利治疗可有效降低心肌梗死患者PCI术后心血管不良事件的发生风险。

Objective To investigate the effects of atorvastatin combined with fosinopril on cardiovascular events after PCI in myocardial infarction.Methods The clinical data and follow-up results of 106 patients with ST segment elevation myocardial infarction(STEMI)treated by percutaneous coronary interention menstruation(PCI)from September 2018 to October 2019 were retrospectively analyzed,the 48 cases of patients with treatment of atorvastatin were group A,58 cases of patients with atorvastatin combined with fosinopril were group B,the clinical data and postoperative cardiovascular adverse events occurred within two months of patients between two groups were compared.Results There was no significant difference in levels of LVEF,LVEDD,CK-MB and cTnl between the two groups after surgery for 7 days.Two months after the operation,9 cases of adverse cardiovascular events occurred in group A and 3 cases of adverse cardiovascular events occurred in group B.The incidence of adverse cardiovascular events in group B was significantly lower than that in group A(χ^(2)=4.823,P=0.028).Conclusion The atorvastatin combined with fosinopril can effectively reduce the risk of cardiovascular adverse events after PCI in patients with myocardial infarction.